Citius Oncology (CTOR) Share-based Compensation (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Share-based Compensation data on file, last reported at $3.7 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 77.36% year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was $3.7 million, a 72.77% decrease from a year earlier, with the FY2025 full-year figure at $8.3 million, down 28.23% from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.7 million, down from $4.0 million in the prior quarter.
• Over the last five years, Share-based Compensation for CTOR reached as high as $11.6 million in Q3 2024 and fell as low as $1.8 million in Q4 2024.
• Historically, Share-based Compensation has averaged $3.9 million across 4 years, with a median of $3.0 million in 2025.
• On a YoY basis, Share-based Compensation climbed as much as 118.75% in 2025 and fell as far as 80.18% in 2025.
• Year by year, Share-based Compensation stood at $1.9 million in 2023, then decreased by 5.66% to $1.8 million in 2024, then soared by 118.75% to $4.0 million in 2025, then decreased by 6.37% to $3.7 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $3.7 million in Q1 2026, $4.0 million in Q4 2025, and $2.3 million in Q3 2025.